Obesity, projected to affect 25% of the world’s population by 2035, demands innovative trial designs. Digital health technologies (DHTs)—including wearables, apps, sensors, and telemedicine—are transforming obesity studies by enabling real-time, continuous data capture, remote monitoring, and patient-friendly participation. Between 2020–2022, trials using DHTs rose 36%, proving their impact on outcomes such as weight loss, BMI reduction, and body fat decrease. Success requires fit-for-purpose devices, regulatory alignment, and logistics planning. IQVIA’s global experience across 500+ studies ensures sponsors harness DHTs effectively, achieving efficiency, compliance, and meaningful patient insights.

Join for free to read